Paras Diabrid® Technology

Diabrid® Technology is a unique propriety technology for the expression of recombinant therapeutic proteins and therapeutic peptides. The technology facilitates a higher expression of therapeutic proteins in a manner that enhances the quality and bio effectiveness of the molecules in addition to facilitating post production protocols.

This has successfully resulted in Paras Biopharmaceuticals Finland Oy being able to offer one of the most economical ways to improve the production of expensive biopharmaceuticals. Within Diabrid Expression Technology, Paras Biopharmaceuticals Finland Oy has incorporated a unique strategy to produce biologics including therapeutic proteins and therapeutic peptides in a way that overcomes the many limitations of traditional methods in the production of biopharmaceuticals.

The genetic construction of propriety plasmids of Paras Biopharmaceuticals Finland Oy are developed with the most optimum genetic codes selected for each amino acid of the therapeutic product. A selective combination is then developed by the most advanced optimization programs available in the industry to achieve the highest levels of protein expressions. Genes are coupled with suitable fusion partners, with a unique combination of therapeutic proteins and therapeutic peptides.

Within Diabrid NobleCleav® technology, a highly innovative platform is used. Specially optimized protocols and procedures are used for the production of biopharmaceuticals together with a very economical method to facilitate highly efficient refolding of the proteins.

Paras Biopharma Technological Approach

Paras Biopharmaceuticals Finland Oy technological approach is solely focused on achieving a successful product development. As a result, there are two main features that drive our technological innovations:

We successfully combine scientific expertise and excellent infrastructure in Finland forming a solid foundation which allows various product and process developments with economics to take centre stage.